AbCellera Biologics Inc. ABCL Accounts payable and other current liabilities
Accounts payable and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s accounts payable and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s accounts payable and other current liabilities?
- AbCellera Biologics Inc. (ABCL) reported accounts payable and other current liabilities of -$9.41M in Q1 2026.
- How has AbCellera Biologics Inc.'s accounts payable and other current liabilities changed year-over-year?
- AbCellera Biologics Inc.'s accounts payable and other current liabilities decreased by 175.9% year-over-year, from -$3.41M to -$9.41M.
- What is the long-term trend for AbCellera Biologics Inc.'s accounts payable and other current liabilities?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s accounts payable and other current liabilities has grown at a 18.2% compound annual growth rate (CAGR), from -$2.09M to $3.46M.
- What does accounts payable and other current liabilities mean?
- This metric represents the net change in short-term obligations owed to suppliers and other creditors during the reporting period. It reflects the company's management of working capital and its timing of cash outflows for operational expenses.